New HIV Vaccine Candidate Shows Promise
Image: Unsplash
22 May 2024
A new HIV vaccine candidate, DHVI, has shown promise in early-stage clinical trials
Image: Unsplash
The vaccine successfully generated broadly neutralising antibodies (bnAbs) in several people after two doses
Image: Unsplash
bnAbs can recognise and neutralise multiple HIV strains, key to an effective HIV vaccine
Image: Unsplash
Generating bnAbs in humans has been difficult, but this vaccine candidate shows potential progress
Image: Unsplash
The clinical trial results were published in the journal Cell, indicating significant scientific validation
Image: Unsplash
More research is needed to confirm the results and determine the vaccine's safety and efficacy
Image: Unsplash
Senior author Barton F Haynes highlighted the importance of inducing potent neutralising antibodies against HIV
Image: Unsplash
The phase 1 trial involved 20 healthy participants, with 15 receiving two doses and five three doses
Image: Unsplash
The vaccine induced strong immune responses, achieving a 95% serum response rate and 100% CD4+ T-cell response
Image: Unsplash
The trial was stopped after one participant had a non-life-threatening allergic reaction to an additive
Image: Unsplash
Check More Stories
Image: Reuters
Image: Unsplash
Image: Unsplash
ndtv.com